FundingWatcher
Home / Startups / Top biotech startups / Biotech startups that raised Series A / Biotech startups that raised Series A in Switzerland

Biotech startups that raised Series A in Switzerland

Updated 16 Nov 2026

Reset
Biotech startups that raised Series A in Switzerland
One-time CSV
  • 56 funded companies, 35 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech--series-a~switzerland.csv56 rows × 18 columns
CompanyCityLast roundAmountDate
Adaptyv BiosystemsLausanneSeries A$40.0M2026-08-25
Leman BiotechLausanneSeries A$28.8M2026-01-26
FoRx TherapeuticsBaselSeries A$50.0M2025-12-18
ComphyaLausanneSeries A$4.0M2025-07-08
AdipossGenevaSeries A$5.0M2025-06-30
RhygazeBaselSeries A$86.0M2025-01-10
NeurosterixGenevaSeries A$65.0M2024-04-03
ScailyteBaselSeries A$1.8M2023-12-04

8 rows of the CSV in 5 of its 18 columns.

56
Startups
$985.6M
Total raised
6
Funded in the last 12 months
$144.0M
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

26 of 56
26 rows
Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
Adaptyv Biosystems Adaptyv Biosystems develops protein engineering tools using cell-free synthetic biology and nanofluidics technology. Artificial intelligence Lausanne Series A $40.0M 2026-08-25 $50.9M Y Combinator, Venture Kick, Acequia Capital (AceCap) +2 11 to 50 2020
Leman Biotech Leman Biotech develops cancer immunotherapies as a biotech company. Biotech Lausanne Series A $28.8M 2026-01-26 $46.8M Tiantu Capital, Fuho Capital 11 to 50 2021
FoRx Therapeutics FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. Biotech Basel Series A $50.0M 2025-12-18 $109.4M EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 11 to 50 2019
Comphya Comphya develops an active implantable medical device to restore erectile function in patients who do not respond to oral drugs. Biotech Lausanne Series A $4.0M 2025-07-08 $14.2M Venture Kick, Verve Ventures, Nest Collective Foundation 1 to 10 2017
Adiposs Adiposs SA is a clinical-stage life science company developing a first-in-class imaging product for cancer patients. Biotech Geneva Series A $5.0M 2025-06-30 $7.4M MassChallenge, Venture Kick, FONGIT Innovation Fund +2 1 to 10 2020
Rhygaze Rhygaze develops a gene therapy that targets cone cells to restore vision in blinding diseases. Biotech Basel Series A $86.0M 2025-01-10 $97.3M Google Ventures, F-Prime, ARCH Venture Partners +2 11 to 50 2024
Neurosterix Neurosterix is a biopharmaceutical firm creating allosteric modulators for neurological illnesses. Biotech Geneva Series A $65.0M 2024-04-03 $65.0M Perceptive Advisors, Xontogeny, Acorn Bioventures 11 to 50 2024
Scailyte Scailyte delivers precision medicine through single-cell science. Artificial intelligence Basel Series A $1.8M 2023-12-04 $15.6M Venture Kick, Verve Ventures, Innosuisse +2 11 to 50 2017
TOLREMO therapeutics TOLREMO therapeutics develops small molecules that target drug resistance pathways in cancer therapy. Biotech Zürich Series A $37.9M 2023-09-20 Altos Ventures, redalpine, BioMedPartners +1 11 to 50 2017
NewBiologix NewBiologix is a technology innovation company. Biotech Epalinges Series A $50.3M 2023-05-11 $50.3M Recipharm Venture Fund 11 to 50 2023
Vector BioPharma Vector BioPharma develops gene precision delivery technology to improve biologics. Biotech Basel Series A $30.0M 2022-08-10 $30.0M Versant Ventures 11 to 50 2021
CDR-Life AG CDR-Life AG develops therapeutic antibody fragments for immuno-oncology. Biotech Schlieren Series A $76.0M 2022-04-13 $76.0M RA Capital Management, Omega Funds, Jeito Capital 51 to 100 2017
Cimeio Therapeutics Cimeio Therapeutics develops curative treatments for genetic diseases, blood cancers, and severe autoimmune disorders. Biotech Basel Series A $50.0M 2022-04-13 $50.0M Versant Ventures 11 to 50 2020
Embion Technologies Embion Technologies offers industrial biomass processing technology for nutrition, pharma, and cosmetics applications. Biotech Lausanne Series A $4.9M 2021-12-08 Venture Kick, Foundation for Innovation and Technology (FIT), Swiss Economic Award 1 to 10 2016
Anjarium Biosciences Anjarium Biosciences develops non-viral gene therapies to treat genetic diseases. Biotech Schlieren Series A $60.4M 2021-09-15 Gimv, Omega Funds, Pfizer Venture Investments +2 1 to 10 2017
Chord Therapeutics Chord Therapeutics is a clinical stage biopharmaceutical company developing drugs for rare diseases. Biotech Geneva Series A $16.0M 2020-10-13 Omega Funds, Eclosion SA 1 to 10 2014
POLYNEURON Polyneuron is a pharmaceutical company developing a new drug class for autoimmune disorders. Biotech Basel Series A $15.4M 2020-09-16 $45.0M New Enterprise Associates, Venture Kick, Sofinnova Partners +1 1 to 10 2014
Arvelle Therapeutics Arvelle Therapeutics is a biopharmaceutical company developing medicines for patients. Biotech Basel Series A $42.7M 2020-05-27 KB Investment, F-Prime, EQT Life Sciences +2 51 to 100 2019
Saphetor Saphetor is a company that develops personalised medicine. Biotech Lausanne Series A $4.2M 2020-03-27 $6.6M Foundation for Innovation and Technology (FIT), GoBeyond, Alpana Ventures +1 51 to 100 2014
Inthera Bioscience Inthera Bioscience develops inhibitors of intracellular protein interactions using a proprietary technology platform. Biotech Schlieren Series A $5.5M 2018-06-26 Microsoft Accelerator, Novo Holdings, M Ventures +2 11 to 50 2013
Intelligent Sensory concept Intelligent Sensory concept is a biotechnology company that specializes in photomodulation. Biotech Geneva Series A $2.0M 2018-05-18 Rhône Finance 11 to 50 2015
PIQUR Therapeutics PIQUR Therapeutics is a Swiss pharmaceutical company developing anti-cancer drugs. Biotech Basel Series A $30.9M 2017-09-01 $86.9M Venture Kick, Versant Ventures 11 to 50 2011
CT Atlantic CT Atlantic researches and develops novel human-derived antibodies for cancer treatment. Biotech Schlieren Series A $9.0M 2009-01-12 HS LifeSciences 1 to 10 2008
Pevion Biotech Pevion Biotech is a biotechnology company that uses its proprietary technology platforms. Biotech Bern Series A $29.2M 2007-08-13 $29.2M BB Biotech Ventures, BZ Bank 11 to 50 2002
4-Antibody AG 4-Antibody AG develops a human antibody drug-discovery platform for immuno-oncology therapeutics. Biotech Basel Series A $18.4M 2007-01-16 $20.6M EQT Life Sciences, BioMedPartners, Grazia Equity +2 251 to 500 2002
Roche Glycart Roche Glycart researches, develops, and commercializes antibody-based biotechnology products. Biotech Schlieren Series A $13.6M 2003-11-26 $13.6M Forbion Capital Partners, Novartis Venture Fund, BioMedPartners +1 101 to 250 2000

Table 1. Biotech startups that raised Series A in Switzerland: the 26 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 56.

Largest rounds

Last 12 months
# Company What they do Sector City Last round Amount Date Total raised Investors Employees Founded
1 FoRx Therapeutics FoRx Therapeutics is a biotechnology company developing cancer drugs that target DNA replication stress pathways. Biotech Basel Series A $50.0M 2025-12-18 $109.4M EQT Life Sciences, Novartis Venture Fund, Omega Funds +2 11 to 50 2019
2 Adaptyv Biosystems Adaptyv Biosystems develops protein engineering tools using cell-free synthetic biology and nanofluidics technology. Artificial intelligence Lausanne Series A $40.0M 2026-08-25 $50.9M Y Combinator, Venture Kick, Acequia Capital (AceCap) +2 11 to 50 2020
3 Leman Biotech Leman Biotech develops cancer immunotherapies as a biotech company. Biotech Lausanne Series A $28.8M 2026-01-26 $46.8M Tiantu Capital, Fuho Capital 11 to 50 2021

Table 2. Biotech startups that raised Series A in Switzerland: the 3 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 Venture Kick Startup incubator Schlieren, Switzerland 10 18% 1 Adaptyv Biosystems
2 Foundation for Innovation and Technology (FIT) Entrepreneurship program Lausanne, Switzerland 5 9% 1 Adaptyv Biosystems
3 Novartis Venture Fund Corporate venture arm Basel, Switzerland 4 7% 1 FoRx Therapeutics
4 Omega Funds Secondary purchaser Boston, United States 4 7% 1 FoRx Therapeutics
5 EQT Life Sciences Private equity firm Amsterdam, The Netherlands 3 5% 1 FoRx Therapeutics
6 BioMedPartners Venture capital firm Basel, Switzerland 3 5%
7 Versant Ventures Venture capital firm Menlo Park, United States 3 5%
8 Pfizer Venture Investments Corporate venture arm New York, United States 2 4% 1 FoRx Therapeutics
9 Verve Ventures Venture capital firm Zug, Switzerland 2 4%
10 F-Prime Venture capital firm Cambridge, United States 2 4%
11 M Ventures Corporate venture arm Amsterdam, The Netherlands 2 4%
12 Gilde Healthcare Private equity firm Utrecht, The Netherlands 2 4%
13 GoBeyond Angel group Zürich, Switzerland 2 4%
14 Momenta Ventures Venture capital firm Meggen, Switzerland 1 2% 1 DataHow
15 Y Combinator Startup accelerator Mountain View, United States 1 2% 1 Adaptyv Biosystems

Table 3. Biotech startups that raised Series A in Switzerland: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 47 84% $744.4M
Software 7 12% $66.5M
Artificial intelligence 6 11% $66.5M
Hardware 1 2%

Table 4. Biotech startups that raised Series A in Switzerland by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Series A 56 100% $9.4M

Table 5. Biotech startups that raised Series A in Switzerland by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Basel 13 23%
Lausanne 10 18%
Schlieren 6 11%
Geneva 5 9%
Epalinges 4 7%
Zürich 3 5%
Neuchâtel 3 5%
Risch 1 2%
Hombrechtikon 1 2%
Pfaffikon 1 2%
Plan-les-ouates 1 2%
Montreux 1 2%

Table 6. Biotech startups that raised Series A in Switzerland by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
October 2026 1 17% $4.8M
September 2026 1 17%
August 2026 1 17% $40.0M
April 2026 1 17% $20.5M
January 2026 1 17% $28.8M
December 2025 1 17% $50.0M

Table 7. Biotech startups that raised Series A in Switzerland: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 5 9% $94.0M
2025 6 11% $210.0M
2024 4 7% $111.0M
2023 5 9% $90.0M
2022 3 5% $156.0M
2021 7 12% $92.5M

Table 8. Biotech startups that raised Series A in Switzerland by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 3 5%
2020 to 2022 9 16%
2015 to 2019 21 38%
2010 to 2014 14 25%
Before 2010 9 16%

Table 9. Biotech startups that raised Series A in Switzerland by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 18 33%
11 to 50 30 55%
51 to 100 5 9%
101 to 250 1 2%
251 to 500 1 2%

Table 10. Biotech startups that raised Series A in Switzerland by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in Switzerland whose last round is Series A are on the list?
56, in the file dated 16 November 2026. 6 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 56 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $199.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups that raised Series A in Switzerland: 56 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $199 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech at other stages in Switzerland

Other sectors that raised Series A in Switzerland

Cite: FundingWatcher, 56 biotech companies in Switzerland whose most recent round is Series A, 16 November 2026. https://fundingwatcher.com/startups/biotech/series-a/switzerland/